New data from a clinical trial using a drug called Nilvadipine—identified by researchers at the Roskamp Institute—shows that patients with very mild (very early-stage) Alzheimer’s disease show less cognitive decline over an 18-month period than placebo-treated patients. On the key clinical measure of memory, the very early stage Alzheimer's cases who were taking Nilvadipine performed better than their placebo-treated counterparts. More than 5.7 million Americans are living with Alzheimer’s Disease—which is the sixth leading cause of death, according to the Alzheimer’s Association—and is the most expensive disease in the country, costing $21 million per hour. This new study took place over 18 months in nine European countries and was largely funded by the European Commission. The results are published today in the scientific journal Frontiers in Neurology; for more information, click here.